Funder: International Association for the Study of Lung Cancer
Due Dates: January 14, 2027, at 12:00 pm (noon) MST (Full application) | May 14, 2027 (Award notification) | July 1, 2027 (Approximate funding start)
Funding Amounts: USD 100,000 per year for up to two years (USD 200,000 total); second-year funding is conditional
Summary: Supports early-career investigators conducting translational lung cancer research to improve detection, diagnosis, treatment, and patient care.
Key Information: Institutions must commit approximately 50% of applicants’ full-time professional effort to research.
Description
The Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) jointly support early-career investigators pursuing innovative translational clinical-oncology research. Projects should make an immediate, relevant impact on lung cancer care or interpret clinical-trial results at a molecular level to inform future trials. The program aims to improve detection, diagnosis, and treatment while reducing the burden of lung cancer.
Research may address molecular risk assessment, molecular diagnostics, early detection, curative-intent therapy, predictors of targeted or immune therapy response, metastatic disease outcomes, treatment side effects, or causes of non-smoking-related lung cancer. Special consideration goes to projects with near-term patient impact, potential to advance rapidly into prospective clinical trials, improved access or outcomes, or direct benefits for underrepresented populations.
